Pregnancy: Controlled clinical data on the use of Privigen in pregnant women are not available. Caution should therefore be exercised with regard to administration during pregnancy. IVIg products have been shown to cross the placenta, increasingly during the third trimester.
Extensive clinical experience of immunoglobulins suggests that no harmful effects on the course of the pregnancy, or on the foetus and the newborn child are to be expected.
Experimental studies of the excipient L-proline carried out in animals found no direct or indirect toxicity affecting pregnancy, embryonal or foetal development.
Breast-feeding: Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry.